FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2170832030> ?p ?o ?g. }

• W2170832030 endingPage "2611" @default.
• W2170832030 startingPage "2604" @default.
• W2170832030 abstract "Purpose NGR-hTNF consists of human tumor necrosis factor α (hTNF-α) fused to the tumor-homing peptide asparagine-glycine-arginine (NGR) able to selectively bind an aminopeptidase N isoform overexpressed on tumor blood vessels. Hypervascularity is a prominent and poor-prognosis feature of malignant pleural mesothelioma (MPM). Currently, there are no standard options for patients with MPM who are failing a front-line pemetrexed-based regimen. We explored safety and efficacy of NGR-hTNF in this setting. Patients and Methods Eligible patients had radiologically documented tumor progression and performance status ≤ 2. Primary study aim was progression-free survival (PFS). NGR-hTNF 0.8 μg/m 2 was given intravenously every 3 weeks. A subsequent cohort of patients received 0.8 μg/m 2 on a weekly basis. Results In the triweekly cohort (n = 43), only one grade 3 drug-related toxicity was noted, and the most common grades 1 to 2 were short-lived chills (71%). The median PFS was 2.8 months (95% CI, 2.3 to 3.3 months). Nineteen patients (44%) had disease control (one had partial response, and 18 had stable diseases) and experienced a median progression-free time of 4.4 months. In the weekly cohort (n = 14), there was no higher toxicity, and median PFS was 3.0 months (95% CI, 1.9 to 4.1 months). Seven patients (50%) had disease control (all stable diseases) and had a median progression-free interval of 9.1 months. In the overall study population (N = 57), median PFS was 2.8 months. Median progression-free time was 4.7 months in twenty-six patients (46%) who achieved disease control. Median survival was 12.1 months. Conclusion The tolerability and disease control of NGR-hTNF 0.8 μg/m 2 weekly warrant additional evaluation in patients with advanced MPM." @default.
• W2170832030 created "2016-06-24" @default.
• W2170832030 creator A5021465650 @default.
• W2170832030 creator A5025322230 @default.
• W2170832030 creator A5026665975 @default.
• W2170832030 creator A5040884103 @default.
• W2170832030 creator A5044577073 @default.
• W2170832030 creator A5045859251 @default.
• W2170832030 creator A5046939478 @default.
• W2170832030 creator A5051537426 @default.
• W2170832030 creator A5051919018 @default.
• W2170832030 creator A5052353123 @default.
• W2170832030 creator A5058513968 @default.
• W2170832030 creator A5059424755 @default.
• W2170832030 creator A5062532607 @default.
• W2170832030 creator A5062656872 @default.
• W2170832030 creator A5068715327 @default.
• W2170832030 creator A5070704228 @default.
• W2170832030 creator A5082045927 @default.
• W2170832030 creator A5088186975 @default.
• W2170832030 creator A5090199263 @default.
• W2170832030 date "2010-05-20" @default.
• W2170832030 modified "2023-09-27" @default.
• W2170832030 title "Phase II Study of Asparagine-Glycine-Arginine–Human Tumor Necrosis Factor α, a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma" @default.
• W2170832030 cites W1559937222 @default.
• W2170832030 cites W1890068101 @default.
• W2170832030 cites W1971211622 @default.
• W2170832030 cites W1972016510 @default.
• W2170832030 cites W1975984380 @default.
• W2170832030 cites W1987724930 @default.
• W2170832030 cites W1989084881 @default.
• W2170832030 cites W1991684762 @default.
• W2170832030 cites W2009403054 @default.
• W2170832030 cites W2019708554 @default.
• W2170832030 cites W2024105041 @default.
• W2170832030 cites W2029409133 @default.
• W2170832030 cites W2031583328 @default.
• W2170832030 cites W2044180798 @default.
• W2170832030 cites W2044717219 @default.
• W2170832030 cites W2057123987 @default.
• W2170832030 cites W2065162646 @default.
• W2170832030 cites W2067583075 @default.
• W2170832030 cites W2077248800 @default.
• W2170832030 cites W2090472525 @default.
• W2170832030 cites W2093121307 @default.
• W2170832030 cites W2094586578 @default.
• W2170832030 cites W2095364726 @default.
• W2170832030 cites W2100576484 @default.
• W2170832030 cites W2101834873 @default.
• W2170832030 cites W2102627969 @default.
• W2170832030 cites W2120009106 @default.
• W2170832030 cites W2130024368 @default.
• W2170832030 cites W2131561057 @default.
• W2170832030 cites W2134594118 @default.
• W2170832030 cites W2138270921 @default.
• W2170832030 cites W2149396308 @default.
• W2170832030 cites W2151439313 @default.
• W2170832030 cites W2169965478 @default.
• W2170832030 cites W2225858252 @default.
• W2170832030 cites W2258438249 @default.
• W2170832030 cites W2268842904 @default.
• W2170832030 cites W4240420638 @default.
• W2170832030 cites W4293241248 @default.
• W2170832030 doi "https://doi.org/10.1200/jco.2009.27.3649" @default.
• W2170832030 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20406925" @default.
• W2170832030 hasPublicationYear "2010" @default.
• W2170832030 type Work @default.
• W2170832030 sameAs 2170832030 @default.
• W2170832030 citedByCount "105" @default.
• W2170832030 countsByYear W21708320302012 @default.
• W2170832030 countsByYear W21708320302013 @default.
• W2170832030 countsByYear W21708320302014 @default.
• W2170832030 countsByYear W21708320302015 @default.
• W2170832030 countsByYear W21708320302016 @default.
• W2170832030 countsByYear W21708320302017 @default.
• W2170832030 countsByYear W21708320302018 @default.
• W2170832030 countsByYear W21708320302019 @default.
• W2170832030 countsByYear W21708320302020 @default.
• W2170832030 countsByYear W21708320302021 @default.
• W2170832030 countsByYear W21708320302022 @default.
• W2170832030 countsByYear W21708320302023 @default.
• W2170832030 crossrefType "journal-article" @default.
• W2170832030 hasAuthorship W2170832030A5021465650 @default.
• W2170832030 hasAuthorship W2170832030A5025322230 @default.
• W2170832030 hasAuthorship W2170832030A5026665975 @default.
• W2170832030 hasAuthorship W2170832030A5040884103 @default.
• W2170832030 hasAuthorship W2170832030A5044577073 @default.
• W2170832030 hasAuthorship W2170832030A5045859251 @default.
• W2170832030 hasAuthorship W2170832030A5046939478 @default.
• W2170832030 hasAuthorship W2170832030A5051537426 @default.
• W2170832030 hasAuthorship W2170832030A5051919018 @default.
• W2170832030 hasAuthorship W2170832030A5052353123 @default.
• W2170832030 hasAuthorship W2170832030A5058513968 @default.
• W2170832030 hasAuthorship W2170832030A5059424755 @default.
• W2170832030 hasAuthorship W2170832030A5062532607 @default.
• W2170832030 hasAuthorship W2170832030A5062656872 @default.
• W2170832030 hasAuthorship W2170832030A5068715327 @default.
• W2170832030 hasAuthorship W2170832030A5070704228 @default.

• next